Is Alzheimer's Prevention a (Soon to Be) New Reality?

By Langbaum, Jessica B. | Aging Today, May/June 2013 | Go to article overview

Is Alzheimer's Prevention a (Soon to Be) New Reality?


Langbaum, Jessica B., Aging Today


Ten years ago, when considering Alzheimer's prevention research, it was predominately limited to healthy lifestyle interventions, vitamins and supplements. This has recently changed, with clinical trials of experimental treatments being tested or planning to be tested in high-risk populations. These populations include, but are not limited to, autosomal dominant Alzheimer's disease mutation carriers, apolipoprotein E (APOE) 4 carriers and older adults with significant fibrillar amyloid deposits. There are many reasons why some researchers, pharmaceutical companies and regulatory agencies are beginning to embrace this approach.

Biological Changes Occur Before Impairment

Perhaps one of the greatest catalysts is the growing evidence from natural history, epidemiological and biomarker studies of individuals at risk for developing Alzheimer's because of age, genetics, family history or other factors. This evidence has led to a greater understanding of disease progression and a recognition that the pathogenic cascade of Alzheimer's disease begins at least one to two decades before cognitive impairment.

Efforts from the Dominantly Inherited Alzheimer's Network (DIAN) and the Alzheimer's Prevention Initiative that were published in 2012 in the New England Journal of Medicine (367; doi:10.10S6/ NEJMcl2U767) and Lancet Neurology (11; doi:10.1016/S1474-4422(12)70228-4), reported that in autosomal dominant Alzheimer's disease mutation carriers, a cascade of biological changes occurs. Fibrillar amyloid plaque deposition- a cardinal neuropathological feature of Alzheimer's-begins approximately 17 years before mild cognitive impairment, rises steeply over the next decade and may plateau prior to the onset of cognitive impairment.

Other biomarkers, such as magnetic resonance imaging (MRI) measures of brain tissue and volume and cerebrospinal fluid (CSF), may show even earlier evidence of abnormalities among mutation carriers. These results generally support the hypothetical dynamic biomarkers of the Alzheimer's disease biological cascade proposed by Dr. Clifford Jack and published in Lancet Neurology in 2010 (9; doi:10.1016/S1474-4422(09)70299-6) and slightly revised in 2013 (12; doi:10. 1016/S1474-4422(12)70291-0).

For some scientists, this "silent" period between when pathological evidence of the disease is present but there are no clinical symptoms may be the ideal period to intervene and test if a treatment to delay cognitive impairment is effective. These studies have also been important in identifying biomarker measurements best able to detect and track changes associated with Alzheimer's- MRI measures of brain tissue, fluorodeoxyglucose positron emission tomography (PET) measures of brain glucose metabolism, PET measures of fibrillar amyloid in the brain and CSF measures of amyloid and tau pathology.

The detailed neuropsychological data collected as part of longitudinal studies have allowed researchers to determine the optimal combination of tests to detect and track presymptomatic cognitive change- creating a test score that can be used in preventive treatment trials. The recent lack of positive results from trials of anti-amyloid therapies in cognitively impaired patients has been used to dismiss amyloidbased treatments. This includes trials of the passive immunotherapies bapineuzumab and solanezumab and the gamma (?) secretase inhibitor semagacestat. Alternatively, these treatments may have been too weak, off target or need to be started earlier, in the silent or preclinical phase of Alzheimer's.

The rest of this article is only available to active members of Questia

Sign up now for a free, 1-day trial and receive full access to:

  • Questia's entire collection
  • Automatic bibliography creation
  • More helpful research tools like notes, citations, and highlights
  • Ad-free environment

Already a member? Log in now.

Notes for this article

Add a new note
If you are trying to select text to create highlights or citations, remember that you must now click or tap on the first word, and then click or tap on the last word.
One moment ...
Project items

Items saved from this article

This article has been saved
Highlights (0)
Some of your highlights are legacy items.

Highlights saved before July 30, 2012 will not be displayed on their respective source pages.

You can easily re-create the highlights by opening the book page or article, selecting the text, and clicking “Highlight.”

Citations (0)
Some of your citations are legacy items.

Any citation created before July 30, 2012 will labeled as a “Cited page.” New citations will be saved as cited passages, pages or articles.

We also added the ability to view new citations from your projects or the book or article where you created them.

Notes (0)
Bookmarks (0)

You have no saved items from this article

Project items include:
  • Saved book/article
  • Highlights
  • Quotes/citations
  • Notes
  • Bookmarks
Notes
Cite this article

Cited article

Style
Citations are available only to our active members.
Sign up now to cite pages or passages in MLA, APA and Chicago citation styles.

(Einhorn, 1992, p. 25)

(Einhorn 25)

1

1. Lois J. Einhorn, Abraham Lincoln, the Orator: Penetrating the Lincoln Legend (Westport, CT: Greenwood Press, 1992), 25, http://www.questia.com/read/27419298.

Cited article

Is Alzheimer's Prevention a (Soon to Be) New Reality?
Settings

Settings

Typeface
Text size Smaller Larger
Search within

Search within this article

Look up

Look up a word

  • Dictionary
  • Thesaurus
Please submit a word or phrase above.
Print this page

Print this page

Why can't I print more than one page at a time?

Full screen

matching results for page

Cited passage

Style
Citations are available only to our active members.
Sign up now to cite pages or passages in MLA, APA and Chicago citation styles.

"Portraying himself as an honest, ordinary person helped Lincoln identify with his audiences." (Einhorn, 1992, p. 25).

"Portraying himself as an honest, ordinary person helped Lincoln identify with his audiences." (Einhorn 25)

"Portraying himself as an honest, ordinary person helped Lincoln identify with his audiences."1

1. Lois J. Einhorn, Abraham Lincoln, the Orator: Penetrating the Lincoln Legend (Westport, CT: Greenwood Press, 1992), 25, http://www.questia.com/read/27419298.

Cited passage

Welcome to the new Questia Reader

The Questia Reader has been updated to provide you with an even better online reading experience.  It is now 100% Responsive, which means you can read our books and articles on any sized device you wish.  All of your favorite tools like notes, highlights, and citations are still here, but the way you select text has been updated to be easier to use, especially on touchscreen devices.  Here's how:

1. Click or tap the first word you want to select.
2. Click or tap the last word you want to select.

OK, got it!

Thanks for trying Questia!

Please continue trying out our research tools, but please note, full functionality is available only to our active members.

Your work will be lost once you leave this Web page.

For full access in an ad-free environment, sign up now for a FREE, 1-day trial.

Already a member? Log in now.